Boston, MA -- (SBWIRE) -- 07/27/2017 -- According to the recently published report 'Mitogen Activated Protein Kinase Kinase Kinase 5 - Pipeline Review, H1 2017'; Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Mitogen-activated protein kinase kinase kinase 5 (MAP3K5) is a member of MAP kinase kinase kinase family encoded by MAP3K5 gene. It plays an important role in the cascades of cellular responses evoked by changes in the environment. It mediates signaling for determination of cell fate such as differentiation and survival. It plays a crucial role in the apoptosis signal transduction pathway through mitochondria-dependent caspase activation. It is essential for host defense against a wide range of pathogens. It mediates signal transduction of various stressors like oxidative stress as well as by receptor-mediated inflammatory signals.

Get More Details on this Report and a Full Table of Contents at Mitogen Activated Protein Kinase Kinase Kinase 5 - Pipeline Review, H1 2017

The report 'Mitogen Activated Protein Kinase Kinase Kinase 5 - Pipeline Review, H1 2017' outlays comprehensive information on the Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Preclinical and Discovery stages are 1, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Central Nervous System, Gastrointestinal, Immunology, Metabolic Disorders, Oncology and Undisclosed which include indications Neurodegenerative Diseases, Non-Alcoholic Steatohepatitis (NASH), Alcoholic Hepatitis, Amyotrophic Lateral Sclerosis, Cardiovascular Disease, Chronic Pain, Cirrhosis, Diabetic Nephropathy, Gastric Cancer, Hepatic Injury, Liver Diseases, Myocardial Infarction, Non Alcoholic Fatty Liver Disease (NAFLD), Pulmonary Hypertension, Rheumatoid Arthritis, Thrombosis and Unspecified.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Report Scope

-The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25)

-The report reviews Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

-The report reviews key players involved in Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics and enlists all their major and minor projects

-The report assesses Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

-The report summarizes all the dormant and discontinued pipeline projects

-The report reviews latest news and deals related to Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics

Reasons to Get this Report

-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Companies Mentioned in this Report: Chipscreen Biosciences Ltd, CJ HealthCare Corp, Gilead Sciences Inc, Kyowa Hakko Kirin Co Ltd, Takeda Pharmaceutical Company Ltd

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:

-Mitogen Activated Protein Kinase Kinase Kinase 7 - Pipeline Review, H1 2017
-Mitogen Activated Protein Kinase 9 - Pipeline Review, H1 2017
-MAP Kinase-Interacting Serine/Threonine-Protein Kinase 1 (Mitogen Activated Protein Kinase-Interacting Kinase 1 or MAP Kinase Signal-Integrating Kinase 1 or EC 2.7.11.1) - Pipeline Review, H1 2016
-MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) - Pipeline Review, H1 2016
-Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) - Pipeline Review, H1 2016